Search Results
Apr 22, 2026, 07:00 ET Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
Apr 22, 2026, 04:30 ET EZVIZ joins the United Nations Global Compact, starting a new chapter of its unwavering journey to long-term sustainability and further expanding its contribution to key environmental issues
environmental protection, as well as to set stricter boundaries to avoid sacrificing the environment for commercial gain."With green in its brand gene, the company has also developed green technology with a low carbon footprint. The AOV low-energy consumption tech, and the ColorFULL low-light night
More news about: EZVIZ
Apr 21, 2026, 23:50 ET kidSTREAM Children's Museum Announces May 21, 2026 Grand Opening
unwavering commitment of early visionaries, dedicated volunteers, and local supporters including Driscoll's and the Gene Haas Foundation, established by the founder of Haas Automation, Gene Haas. Major donor, Ventura County-headquartered biotech firm Amgen donated $1 million, while Amgen Foundation, its
More news about: kidSTREAM Children's Museum
Apr 21, 2026, 22:10 ET Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
using Ractigen's proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial ALS. By reducing the production of the toxic mutant SOD1 protein, RAG-17
More news about: Ractigen Therapeutics
Apr 21, 2026, 16:15 ET BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment
More news about: BioLife Solutions, Inc.
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
metastatic GEA. The FDA granted two Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC, and one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+
More news about: Jazz Pharmaceuticals plc
Apr 21, 2026, 16:00 ET ISCT Announces Inaugural CGT Clinical Applications Program for Clinical Fellows
International Society for Cell & Gene TherapyEstablished in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective
More news about: International Society for Cell & Gene Therapy
Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
positive (EGFRm) NSCLC.Non-small cell lung cancer is the leading cause of cancer death in the world. Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for NSCLC. Multiple agents can be used to treat patients with EGFR mutated NSCLC who develop resistance to EGFR
More news about: Dizal Pharmaceutical
Apr 21, 2026, 11:00 ET ALKU Opens West Coast Office to Expand Life Sciences Staffing Services.
life sciences team leverages the company's exclusive consultant network to place highly skilled talent across the pharmaceutical, biotech, cell and gene therapy, medical device, diagnostics, and combination product sectors. The team specializes in delivering consultants with expertise in:Quality
More news about: ALKU
Apr 21, 2026, 08:00 ET Andelyn Biosciences and ENCell Co., Ltd Announce Strategic Partnership to Expand Global Reach of Gene Therapy Manufacturing
development and scalable production of gene therapies, supporting our clients from early-stage development through global clinical trials and commercialization."The partnership provides an opportunity to accelerate and expand patients' access to life-changing gene therapies, delivering on Andelyn's
More news about: Andelyn Biosciences
Apr 21, 2026, 08:00 ET Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX:
More news about: Minaris Advanced Therapies
Apr 21, 2026, 08:00 ET Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX:
More news about: Minaris Advanced Therapies
Apr 21, 2026, 08:00 ET DuPont Launches Liveo™ Pharma TPE Overmolded Assemblies for Pharma and Biopharma Applications
Diana Salvadori, DuPont™ Liveo™ Global Senior Product Marketing Manager. "These OMAs are well‑suited for applications such as gene therapies; leak‑free connections; and other high‑value, critical applications, including fill‑and‑finish operations."To learn more about
More news about: DuPont
Apr 21, 2026, 07:00 ET Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based
More news about: Genprex, Inc.
Apr 21, 2026, 07:00 ET Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
poster at ACMS, taking place in Austin, Texas, from April 30-May 3, 2026, are as follows: ePoster title: The 31-gene expression profile test stratifies melanoma-specific survival among patients with AJCC T1a and T1b cutaneous melanoma: A 5-year outcome SEER population
More news about: Castle Biosciences, Inc.
Apr 21, 2026, 07:00 ET Pharmactive Launches Kyoh® for Hair Growth Support
cultured human dermal papilla cells, which play a central role in the regulation of hair growth. The ingredient has displayed capabilities in modulating gene activity closely associated with hair growth and follicle cycling in particular, vascular endothelial growth factor (VEGF). VEGF is involved in the
More news about: Pharmactive Biotech Products, S.L.U.
Apr 21, 2026, 06:30 ET Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
entry and gene expression, optimized lipid nanoparticles for redosing and targeted tissue delivery, AI-guided DNA sequence design for cell-specific programmable gene expression, and scalable manufacturing for accessible therapeutics. Unlike RNA therapies that are limited to transient gene expression,
More news about: Flagship Pioneering
Apr 20, 2026, 22:10 ET Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
capture.About Rznomics Inc.Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications.
More news about: Rznomics
Apr 20, 2026, 13:11 ET The Inner Circle acknowledges Clinton Jones as a Pinnacle Professional Member Inner Circle of Excellence
under stress—challenging decades of assumptions that herpesviruses reside exclusively in sensory neurons. His research also identified the only viral gene expressed in latently infected neurons, findings that have had broad implications across human and animal health.Dr. Jones' investigations into
More news about: The Inner Circle
Apr 20, 2026, 12:07 ET Ecovyst to Host First Quarter 2026 Earnings Conference Call and Webcast on Tuesday, May 5, 2026 at 11:00 a.m. ET
https://www.ecovyst.com.Investor Contact:Gene Shiels(484) 617 [email protected]
More news about: Ecovyst Inc.
Apr 20, 2026, 10:51 ET St. David's South Austin Medical Center first in world to enroll patient in clinical trial evaluating a next-generation treatment for aggressive large B-cell lymphoma
trial activation and successfully enrolled the first patient globally. These collaborations bring early-phase clinical trials and advanced cell and gene therapies to patients in Central Texas, offering access to promising new treatments without having to travel far from home. As the
More news about: St. David's South Austin Medical Center
Apr 20, 2026, 09:00 ET Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
medicines using its in vivo gene placement system (iGPS®). Kelonia's elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modification to improve in vivo gene transfer efficiency and tropism molecules
More news about: Eli Lilly and Company
Apr 20, 2026, 09:00 ET Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
platform, an integrated Design, Make, Test solution for RNA therapeutic development. The platform supports programs across vaccines, CAR-T therapies, gene editing, and protein replacement.
More news about: Eclipsebio
Apr 20, 2026, 09:00 ET Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)
care." About Orsini Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Apr 20, 2026, 08:00 ET Pioneer Celebrates a Century of Innovation, Delivering for Farmers
1926 to new hybrid wheat technology today – and Pioneer, as its name suggests, has always been at the leading edge of innovation. And with tools like gene editing on the horizon, we know that after the remarkable past century, Pioneer is only just getting started."Pioneer has led the industry for
More news about: Corteva Agriscience